top
Search terms
Results 31 - 40 of 156 - ordered by :
Pages: 1 2 3 4 5 6 7 ... 16
Escardio

Efficacy and safety of dual antiplatelet therapy and risk stratification tools 3.1 DAPT for the prevention of stent thrombosis 3.2 DAPT for the prevention of spontaneous myocardial infarction 3.3 ...

Date : 26/08/2017
Escardio

Monday 28 August Date & Location Type of session Title 28/08/2017 07:30 Agora 2, Agora Cardiology@breakfast Artificial intelligence - Smartphone apps and new technologies (for use in clinical ...

Date : 21/08/2017
Escardio

[...]there is substantial variation in the estimated 10-year risk of recurrent vascular events, even if all modifiable risk factors are treated until the treatment target is reached. Access the ...

Date : 30/06/2017
Ehjournal

Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study Methods and results Acute coronary syndrome ...

European Heart Journal, Hauguel-Moreau, Marie, Boccara, Franck, Boyd, Anders, Salem, Joe-Elie, Brugier, Delphine, Curjol, Angélique, Hulot, Jean-Sébastien, Kerneis, Mathieu, Galier, Sophie, ...

Date : 01/06/2017 Item size : 389975 bytes
Ehjournal

Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of ...

European Heart Journal, Palmerini, Tullio, Della Riva, Diego, Benedetto, Umberto, Bacchi Reggiani, Letizia, Feres, Fausto, Abizaid, Alexandre, Gilard, Martine, Morice, Marie-Claude, Valgimigli, ...

Date : 07/04/2017 Item size : 357268 bytes
Ehjournal

Management of patients undergoing percutaneous vascular interventions: balancing ischaemic benefit and bleeding risk Since the seminal development of catheter-based balloon angioplasty of vascular ...

European Heart Journal, Lüscher, Thomas F.

Date : 07/04/2017 Item size : 242859 bytes
Ehjournal

In the first of a two-part review, we discuss the choice of NOAC for stroke prevention in the following subgroups of patients with AF: (i) stable coronary artery disease or peripheral artery disease, ...

European Heart Journal, Diener, Hans-Christoph, Aisenberg, James, Ansell, Jack, Atar, Dan, Breithardt, Günter, Eikelboom, John, Ezekowitz, Michael D., Granger, Christopher B., Halperin, Jonathan ...

Date : 21/03/2017 Item size : 490669 bytes
Ehjournal

In the first of a two-part review, we discuss the choice of NOAC for stroke prevention in the following subgroups of patients with AF: (i) stable coronary artery disease or peripheral artery disease, ...

European Heart Journal, Diener, Hans-Christoph, Aisenberg, James, Ansell, Jack, Atar, Dan, Breithardt, Günter, Eikelboom, John, Ezekowitz, Michael D., Granger, Christopher B., Halperin, Jonathan ...

Date : 21/03/2017 Item size : 526847 bytes
Ehjournal

In the first of a two-part review, we discuss the choice of NOAC for stroke prevention in the following subgroups of patients with AF: (i) stable coronary artery disease or peripheral artery disease, ...

European Heart Journal, Diener, Hans-Christoph, Aisenberg, James, Ansell, Jack, Atar, Dan, Breithardt, Günter, Eikelboom, John, Ezekowitz, Michael D., Granger, Christopher B., Halperin, Jonathan ...

Date : 09/03/2017 Item size : 483367 bytes
Ehjournal

Percutaneous coronary intervention (PCI) induces thrombin generation and is associated with the risk of acute, subacute, or long-term ischaemic events. [...]intravenous anticoagulation is ...

European Heart Journal, Zeymer, Uwe, Rao, Sunil V., Montalescot, Gilles

Date : 01/12/2016 Item size : 471841 bytes